Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation

BMC Cancer

Research Article

Jun Gao¹  Wenbing Sun¹  Jian Kong¹  Shuying Dong¹  Jinge Kong²  Fandong Kong²  Bing Pan³  Lemin Zheng³  Liang Ji³  Lian Chen⁴ 

[1] Department of Hepatobiliary Surgery, Beijing Chao-yang Hospital, Capital Medical University, 100043, Beijing, China;Department of Neurobiology, School of Basic Medical Sciences, The Neuroscience Research Institute, Peking University, 100191, Beijing, China;Key Laboratory for Neuroscience, Ministry of Education/National Health and Family Planning Commission, Peking University, 100191, Beijing, China;School of Basic Medical Sciences, and Key Laboratory of Molecular Cardiovascular Sciences of Ministry of Education, The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, Peking University Health Science Center, 100191, Beijing, China;The 8th Department of Orthopaedics, Affiliated Mindong Hospital of Fujian Medical University, 355000, Fujian, China;

关键词: Hepatocellular carcinoma;    Insufficient radiofrequency ablation;    Epithelial-mesenchymal transition;    Sorafenib;   

DOI  :  10.1186/s12885-015-1949-7

 received in 2014-08-08, accepted in 2015-11-20,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundEpithelial-mesenchymal transition (EMT) played an important role in the progression of hepatocellular carcinoma (HCC) after insufficient radiofrequency ablation (RFA). However, whether sorafenib could be used to suppress the EMT of HCC after insufficient RFA and further prevent the progression of residual HCC remains poorly unknown.MethodsInsufficient RFA was simulated using a water bath (47 °C 5, 10, 15, 20 and 25 min gradually). MTT assay and transwell assay were used to evaluate the effects of sorafenib on viability, migration and invasion of HepG2 and SMMC7721 cells after insufficient RFA in vitro. After insufficient RFA, the molecular changes in HCC cells with the treatment of sorafeinb were evaluated using western blot and ELISAs. An ectopic nude mice model was used to evaluate the effect of sorafenib on the growth of HepG2 cells in vivo after insufficient RFA.ResultsHepG2 and SMMC7721 cells after insufficient RFA (named as HepG2-H and SMMC7721-H) exhibited enhanced viability, migration and invasion in vitro. Sorafenib inhibited the enhanced viability, migration and invasion of HepG2 and SMMC7721 cells after insufficient RFA. Molecular changes of EMT were observed in HepG2-H and SMMC7721-H cells. Sorafenib inhibited the EMT of HepG2-H and SMMC7721-H cells. HepG2-H cells also exhibited larger tumor size in vivo. Higher expression of PCNA, Ki67, N-cadherin, MMP-2 and MMP-9, was also observed in HepG2-H tumors. Sorafenib blocked the enhanced growth of HepG2 cells in vivo after insufficient RFA.ConclusionsSorafenib inhibited the EMT of HCC cells after insufficient RFA, and may be used to prevent the progression of HCC after RFA.

【 授权许可】

CC BY   
© Dong et al. 2015